XCMG Advances Belt and Road Talent Cooperation with Launch of Joint Education Programs for Students from Uzbekistan and Indonesia

XUZHOU, China, Oct. 27, 2026 /PRNewswire/ — XCMG Group recently held opening ceremonies in Xuzhou for joint education programs for students from Uzbekistan and Indonesia, advancing youth talent development in Belt and Road partner countries through international education partnerships. Combining language and academic study with technical training and workplace practice, the…

Continue Reading

ABB turns aging drives into a second life at ACC’s Jamul plant, without stopping production

To date, on-site drive reconditioning has preserved capital and material value, avoided ~16 metric tons of CO₂ emissions, and maintained continuity, delivering environmental, economic, and operational value in one decision. Asset health assessment by ABB helped the major Indian cement producer choose a tailored, multi-year ABB Motion OneCare agreement, for…

Continue Reading

India Clears Regulatory Path for E100 Fuel in Flex-Fuel Vehicles: Key Changes Explained

New Delhi, Oct 27: India has taken a significant step towards expanding the use of ethanol-based fuels, with the Ministry of Road Transport and Highways (MoRTH) amending the Central Motor Vehicles Rules, 1989, to include E100 fuel in the regulatory framework for compatible flex-fuel vehicles.  Representational Image The amendment, notified…

Continue Reading

Odisha on High Alert as Cyclone Ornab Intensifies; Heavy Rain Forecast for Three Days

Bhubaneswar, Oct 27: Odisha has stepped up its disaster preparedness as Cyclone Ornab intensifies over the sea, with heavy to extremely heavy rainfall and strong winds forecast across several districts between October 27 and 29.  Representational Image  According to the India Meteorological Department (IMD), the very severe cyclonic storm is…

Continue Reading

TILT Biotherapeutics Presents Encouraging Phase 1b Results in Ovarian Cancer at ESMO 2026

Four of nine evaluable patients responded to TILT-123 combined with pembrolizumab and pegylated liposomal doxorubicin, including two complete responses Helsinki, Finland – Oct 26: TILT Biotherapeutics (TILT), a clinical-stage biotechnology company developing intravenously delivered cancer immunotherapies, today announces preliminary safety and efficacy results from the Phase 1b portion of its…

Continue Reading